A 3D illustration of prostate cancer cells.

The clinical studies of ENZAMET, conducted by the South Australian Immunogenetic Cancer Institute (SAiGENCI), operating within the University of Adelaide have been completed.

The results of their clinical trials were published in The Lancet Oncology.

ENZAMET (ANZUP 1304) is a global collaborative investigator-initiated trial led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).

For people with metastatic hormone-sensitive prostate cancer, the addition of an androgen receptor blocker with enzalutamide to standard therapy – suppression of testosterone, with or without chemotherapy – led to a 67 per cent survival rate after five years.

This compares to 57 per cent of people who were alive after five years after receiving the standard best practice treatment.

Co-chairman of the study Professor Christopher Sweeney, Director of the South Australian ImmunoGENomics Cancer Institute (SAiGENCI), “The longer-term analysis showed that the benefit of adding enzalutamide was evident in all patient subgroups, regardless of when the cancer was found to have spread, or how much was present, or whether people also received docetaxel chemotherapy,” said

“These high level findings indicate that the addition of enzalutamide should be considered as a treatment option for any patient able to receive it.

“The exploratory findings indicate it might not be necessary to add other treatments like chemotherapy.”

The side effects of the addition of enzalutamide to standard of care were overall similar to what has been experienced with enzalutamide in previous clinical trials.

Metastatic prostate cancer is cancer that has spread from the prostate to other parts of the body which can be seen on conventional CT and/or bone scans.

Patients with metastatic hormone sensitive prostate cancer are patients who are starting treatment for metastatic disease and will most likely respond to suppression of the male sex hormone testosterone.

“ENZAMET was the first trial to show a survival benefit from addition of enzalutamide, and the first to include patients receiving docetaxel chemotherapy at the same time,” Professor Sweeney said.

University of Adelaide